Previous 10 | Next 10 |
Company Is Successfully Executing on Multi-Faceted Strategy to Bring Leronlimab to Market Activist Group Offers No New Compelling Strategic Direction and its “Plan” Includes Numerous Misrepresentations and Misleading Statements Activist Group’s Con...
A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of...
3 Penny Stocks to Watch in October 2021 With the month of October fast approaching, many investors are looking for the best penny stocks to buy. While it is still around a week or so away, being proactive can mean the difference between making money with penny stocks and losing mone...
Plan Designed to Generate Much-Needed Revenue and Receive FDA Approval for Currently Mismanaged Drug B elieves Company Cannot Continue to Pursue Status Quo Strategy, Which Has Been Abjectly Discredited A group of long-time stockholders (the “Nominating Sto...
Palm Beach, FL – September 22, 2021 – FinancialNewsMedia.com News Commentary – The U.S. government, via the American Rescue Plan, is investing more than $3 billion to accelerate the discovery, development and manufacturing of antiviral medicines as part of t...
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Brazil’s regulatory authority, ANVISA (Ag...
CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Dr. Scott Kelly, CytoDyn’s Chairman of th...
Nominating Stockholders Fully Committed to Proxy Contest and Electing Director Candidates A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) th...
Are These Penny Stocks On your Watch List Today? Is the stock market safe? Whether you’re trading penny stocks or higher-priced names, it’s hard to ignore what’s transpired over the last week. The S&P, Nasdaq, Dow, and Small-Cap indexes have all pulled back. Tha...
Activist Group Made Numerous Concessions, Including Dissolving Schedule 13D Group and Making Corrective and New Disclosures New Disclosures Clearly Show Activist Group Has Been Misleading Shareholders Around Group’s Conflicts of Interest, Sources of Funding and Agenda ...
News, Short Squeeze, Breakout and More Instantly...
Terms of the settlement include $12,000,000 cash payment to CytoDyn and elimination of $14,000,000 accounts payable liability from the Company’s balance sheet VANCOUVER, Washington, July 09, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a bio...
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that its preclinical MASH study with SMC ...
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executiv...